Back
Speaker illustration

undefined undefined undefined

Presentations

Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Congestion, SGLT2 inhibitors and novel therapies

Access
Like
Thumbnail

Effect of angiotensin converting enzyme inhibitors versus angiotensin receptor blockers on all-cause mortality in heart failure patients receiving quadruple guideline directed medical therapy

Event: Heart Failure 2025

Topic: Pharmacotherapy

Session: Tailored therapeutics advances in heart failure

Access
Like
Thumbnail

Impact of defibrillators on mortality in patients with quadruple guideline-directed medical therapy: a propensity score-matched study

Event: Heart Failure 2024

Topic: Implantable Cardioverter-Defibrillator (ICD)

Session: Acute, advanced and worsening heart failure: prognostic aspects

Access
Like
Thumbnail

Survival analysis in heart failure and end-stage chronic kidney disease: a propensity score matched study comparing peritoneal dialysis and hemodialysis

Event: Heart Failure 2024

Topic: Comorbidities

Session: Treating heart failure with diabetes and renal disease

Access
Like
Thumbnail

How can we increase adherence to medical treatment in heart failure patients? A questionnaire study

Event: Heart Failure 2024

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: Chronic heart failure - pathophysiology and mechanisms 13

Access
Like
Thumbnail

Is bendopnea associated with atrial fibrillation in heart failure patients with reduced ejection fraction?

Event: Heart Failure 2023

Topic: Clinical

Session: ePosters in chronic heart failure 3

Access
Like
Thumbnail

ESC 365 is supported by

novartis Explore sponsored resources